<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04012905</url>
  </required_header>
  <id_info>
    <org_study_id>17-249</org_study_id>
    <secondary_id>2018-000344-25</secondary_id>
    <nct_id>NCT04012905</nct_id>
  </id_info>
  <brief_title>Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering</brief_title>
  <acronym>CORTODOSE</acronym>
  <official_title>A Randomized, Controled, Open Label Trial: Comparison Between Two Standardized Corticosteroids Tapering, Respectively Short (North American) and Long (European), in Giant Cell Arteritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amiens University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital Saint Quentin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital, Valenciennes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital, Lisieux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corticosteroid therapy has always been the standard treatment for giant cell arteritis (GCA),&#xD;
      with very good initial clinical efficacy but a high relapse rate when it declines.&#xD;
&#xD;
      The target population of this condition, often elderly, is particularly exposed to the&#xD;
      numerous undesirable effects of corticosteroid therapy, and this especially as its duration&#xD;
      lengthens with the re-increases of doses according to relapses: metabolic complications,&#xD;
      osteo-muscular , infectious or neuropsychiatric.&#xD;
&#xD;
      Investigators propose to compare prospectively the results of a &quot;conventional&quot; corticosteroid&#xD;
      regimen as recommended by European societies, to those of a &quot;lighter and / or shorter&quot;&#xD;
      scheme, inspired by recent North American trials. , including the largest prospective global&#xD;
      study in the field. Investigators hypothesize non-inferiority of the lightened regimen for&#xD;
      relapse rate without relapse at S52, but with a decrease in treatment-related adverse events&#xD;
      whose cumulative doses should be lower.&#xD;
&#xD;
      Investigators therefore plan to include prospectively over 3 years 150 patients, 75 for each&#xD;
      of the two arms, with a newly diagnosed ACG. A randomization of the treatment arm will be&#xD;
      performed and a predefined pattern of cortisone adapted to body weight will be given to the&#xD;
      patient. Relapse rates, maintenance of remission, cumulative doses of cortisone and adverse&#xD;
      effects of treatment will be analyzed at the 52nd week of the introduction of corticosteroid&#xD;
      therapy. An interim analysis is planned at S28.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of giant cell arteritis (GCA) relies on the use of glucocorticoids (GC), with a&#xD;
      very good clinical response at treatment initiation. However, relapses at GC tapering are&#xD;
      frequent. GCA population is elderly, frequently over 80 years, and is especially affected by&#xD;
      GC-related side effects, that increase proportionally with treatment duration. Thus,&#xD;
      metabolic, musculo-skeletal, infectious or neuro-psychiatric complications are frequent&#xD;
      during prolonged GC use.&#xD;
&#xD;
      After GC introduction, gradual tapering is scheduled, provided the disease remains clinically&#xD;
      and biologically controlled. In France, guidelines recommend tapering GC on an 18-24 months&#xD;
      timeframe, while other countries, such as the USA, usually taper GC over a shorter period,&#xD;
      often 6-8 months. Few comparative data exist on the relapse rates or the GC-related side&#xD;
      effects in both settings. In this prospective multicenter study, two GC-tapering schedules&#xD;
      are planned: patients in one arm (short treatment) will be treated for 28 weeks, while&#xD;
      patients in the second arm will be treated for 52 weeks. Each starting dose of GC and&#xD;
      tapering doses will be adapted to body weight. The primary endpoint is to compare the&#xD;
      remission rate without relapse at W52 between the two groups and the secondary endpoints are:&#xD;
      1) cumulative GC doses at W52; 2) GC-related side effects and 3) number of relapses (minor&#xD;
      and severe) in both arms at W52.&#xD;
&#xD;
      The results of this study might considerably modify future French clinical practice if&#xD;
      investigators confirm that a shorter GC treatment does not significantly impact the disease&#xD;
      course while reducing GC-related side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 5, 2020</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient in complete remission over a follow up of 52 weeks, without relapse</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>First relapses rate at S28 and S52</measure>
    <time_frame>Weeks 28 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second relapses rate at S28 and S52</measure>
    <time_frame>Weeks 28 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay between first and second relapses</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative and the average dose of prednisone used</measure>
    <time_frame>Weeks 28 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient with corticosteroids dependence at week 52</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety according CTCAE v5.0</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Giant Cell Arteritis</condition>
  <arm_group>
    <arm_group_label>Short tapering corticosteroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Corticosteroid taper over 28 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long tapering corticosteroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corticosteroid taper over 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids for Systemic Use</intervention_name>
    <description>Corticosteroids tapering over 28 weeks:&#xD;
J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg&#xD;
Corticosteroids tapering over 52 weeks:&#xD;
J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month</description>
    <arm_group_label>Long tapering corticosteroids</arm_group_label>
    <arm_group_label>Short tapering corticosteroids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 50 years&#xD;
&#xD;
          -  Patient with temporal arteritis giant cell match 2 of the 4 criteria of the American&#xD;
             College of Rheumatology (ACR) that given :&#xD;
&#xD;
               -  a temporal artery biopsy compatible with a diagnosis of CAG or&#xD;
&#xD;
               -  an abdominal thoracic aortitis diagnosed by Angio CT, MR angiography or PET&#xD;
                  scanner or&#xD;
&#xD;
               -  Echo Doppler compatible with a diagnosis of CAG&#xD;
&#xD;
          -  Oral corticosteroid treatment started up to 14 days, the initial dose is less or equal&#xD;
             to 1 mg / Kg&#xD;
&#xD;
          -  Patient wo has given its written consent Patient affiliated with a social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects checking one of the criteria for non-inclusion may be eligible to participate in&#xD;
        the research. These criteria may include:&#xD;
&#xD;
          -  Early treatment of CAG disease with a dose&gt; 1 mg / kg whatever the duration&#xD;
&#xD;
          -  Corticosteroids already started over 14 days&#xD;
&#xD;
          -  Giant arteritis cell on relapse&#xD;
&#xD;
          -  dementia syndrome&#xD;
&#xD;
          -  No compliant patient&#xD;
&#xD;
          -  Patients who live more than 150 km from the investigation center&#xD;
&#xD;
          -  Person under judicial protection, guardianship&#xD;
&#xD;
          -  Hypersensitivity to prednisone or any of its excipients&#xD;
&#xD;
          -  Infection requiring an systemic treatment&#xD;
&#xD;
          -  Evolutive viroses (Hepatitis, Herpes, varicella-zoster virus)&#xD;
&#xD;
          -  Immunization with live vaccines / mitigated during the 8 weeks preceding inclusion&#xD;
&#xD;
          -  Pregnancy, breastfeeding women or women of childbearing potential not using&#xD;
             contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert De BOYSSON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hubert De BOYSSON, MD</last_name>
    <phone>02 31 06 57 32</phone>
    <phone_ext>+33</phone_ext>
    <email>deboysson-h@chu-caen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Audrey SULTAN, PhD</last_name>
    <phone>02 31 06 33 58</phone>
    <phone_ext>+33</phone_ext>
    <email>sultan-a@chu-caen.fr</email>
  </overall_contact_backup>
  <reference>
    <citation>Bienvenu B, Ly KH, Lambert M, Agard C, André M, Benhamou Y, Bonnotte B, de Boysson H, Espitia O, Fau G, Fauchais AL, Galateau-Sallé F, Haroche J, Héron E, Lapébie FX, Liozon E, Luong Nguyen LB, Magnant J, Manrique A, Matt M, de Menthon M, Mouthon L, Puéchal X, Pugnet G, Quemeneur T, Régent A, Saadoun D, Samson M, Sène D, Smets P, Yelnik C, Sailler L, Mahr A; Groupe d'Étude Français des Artérites des gros Vaisseaux, under the Aegis of the Filière des Maladies Auto-Immunes et Auto-Inflammatoires Rares. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne. 2016 Mar;37(3):154-65. doi: 10.1016/j.revmed.2015.12.015. Epub 2016 Jan 29.</citation>
    <PMID>26833145</PMID>
  </reference>
  <reference>
    <citation>de Boysson H, Aouba A. Abatacept as Adjunctive Therapy for the Treatment of Giant Cell Arteritis: Comment on the Article by Langford et al. Arthritis Rheumatol. 2017 Jul;69(7):1504. doi: 10.1002/art.40105. Epub 2017 May 10.</citation>
    <PMID>28324917</PMID>
  </reference>
  <reference>
    <citation>van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom-Bakkers MA, Buttgereit F, Caeyers N, Cutolo M, Da Silva JA, Guillevin L, Kirwan JR, Rovensky J, Severijns G, Webber S, Westhovens R, Bijlsma JW. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010 Nov;69(11):1913-9. doi: 10.1136/ard.2009.124958. Epub 2010 Aug 6.</citation>
    <PMID>20693273</PMID>
  </reference>
  <reference>
    <citation>Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003 Oct 15;49(5):703-8.</citation>
    <PMID>14558057</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 5, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Giant Cell Arteritis</keyword>
  <keyword>Horton disease</keyword>
  <keyword>Corticosteroids treatment</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Relapse</keyword>
  <keyword>Side effect</keyword>
  <keyword>Cumulative doses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All individual data will be analyzed in University Hospital, Caen</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

